sparsentan + No sparsentan
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuric Renal Disease
Conditions
Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Trial Timeline
Mar 1, 2026 → Dec 1, 2028
NCT ID
NCT07224776About sparsentan + No sparsentan
sparsentan + No sparsentan is a phase 1 stage product being developed by Travere Therapeutics for Proteinuric Renal Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07224776. Target conditions include Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria.
What happened to similar drugs?
1 of 1 similar drugs in Proteinuric Renal Disease were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07224776 | Phase 1 | Recruiting |
Competing Products
4 competing products in Proteinuric Renal Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aliskiren + Valsartan | Novartis | Approved | 35 |
| Inaxaplin | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-147 + Placebo | Vertex Pharmaceuticals | Phase 2/3 | 45 |
| MZE829 | Maze Therapeutics | Phase 2 | 36 |